Evidence map›Paper›PMID 41190726›Full record

ArticleImmunotherapy2025

Remarkable response to anti-PD-L1 blockade in relapsed and refractory metastatic malignant giant cell tumor of bone: a case report.

Jerry T Wu, Jarrell Imamura, Elizabeth Nowak, Jessica Leng, John Reith, Scott Kilpatrick, Gary K Schwartz, Zachary D C Burke

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jerry T WuCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
Jarrell ImamuraGenome Medicine Institute, Cleveland Clinic Research, Cleveland Clinic, Cleveland, OH, USA.
Elizabeth NowakGenome Medicine Institute, Cleveland Clinic Research, Cleveland Clinic, Cleveland, OH, USA.
Jessica LengCase Western Reserve University School of Medicine, Cleveland, OH, USA.
John ReithAnatomic Pathology, Robert J. Tomsich Department of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA.
Scott KilpatrickAnatomic Pathology, Robert J. Tomsich Department of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA.
Gary K SchwartzCase Western Reserve University School of Medicine, Cleveland, OH, USA.
Zachary D C BurkeCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

caseA 40-year-old man presented with malignant giant cell tumor of bone of the left distal femur. Despite distal femur resection/replacement and adjuvant chemotherapy, he experienced local recurrence and lung metastases. Salvage radiation therapy was ineffective. Biopsy of the tumor showed a PD-L1 tumor proportion score of 40%. Pembrolizumab was initiated and resulted in a major partial response. However, the patient experienced radiation recall pneumonitis necessitating stoppage of pembrolizumab. The patient then experienced another local recurrence.

conclusionPD-L1 blockade should be considered for MGCTB expressing PD-L1. Unfortunately, pembrolizumab was stopped, which likely allowed for tumor progression in this case.

Indexed as

Antibodies, Monoclonal, HumanizedB7-H1 AntigenBone NeoplasmsGiant Cell Tumor of BoneImmune Checkpoint InhibitorsLung NeoplasmsNeoplasm Recurrence, LocalAdultHumansMaleTreatment OutcomeAntibodies, Monoclonal, HumanizedB7-H1 AntigenCD274 protein, humanImmune Checkpoint InhibitorspembrolizumabImmune checkpoint blockadeimmunotherapymalignant giant cell tumor of boneradiation therapysarcoma

Identifiers

PMID41190726
PMCPMC12607342

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.